Stemgenix has agreed to acquire the Stem Cell Biology Division of GenCyte LLC, an Amherst, NY biotechnology company at which Dr. Swartzwelder and two other Stemgenix founders are currently employees. GenCyte had been focused on discovering genes and identifying targets that will lead to new and improved products for the diagnosis and treatment of human cancers. The Company was positioned to bring revolutionary and proprietary products to the marketplace that will allow for simple and early detection of cancer and innovative therapeutic strategies., Gencyte engaged in the pre-clinical development of a novel biopharmaceutical for breast cancer. This technology is also being exploited to develop a serum assay for the early detection of breast cancer.
